Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- QLT Q3 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you, sir. (Operator's Instructions) Our first question today comes from John Gibbons of Odeon Partners. John Gibbons - Odeon Partners Hi, gentlemen. Nice support — thank you for all the updates. Bob, can you just explain to me or remind me again the...
- Earnings calls 2009-10-27
Additional Resources
- Genentech Finds No Friends in Lucentis Pricing Flap
- Negative public opinion just keeps piling on to Genentech regarding its pricing policy on Lucentis and Avastin. This weekend saw a big Associated Press story describe how the company is refusing to ask the FDA to approve Avastin for use in treating "wet age-related macular degeneration," an eye condition that...
- Blog posts 2008-09-02
- Eye drug's promise.(Genentech to introduce Lucentis)(Brief Article)
- A new drug for age-related macular degeneration is likely to be a big hit. Lucentis, from Genentech, may be fast-tracked by the Food and Drug Administration, putting it on the market next year. The drug can restore some lost vision for people with ...
- Research articles 2005-07-15
- Open-Label Uncontrolled Study of Lucentis Showed Improvement in Vision With Five to Six Doses at One Year
- MIAMI -- The University of Miami's Bascom Palmer Eye Institute announced today the one-year results of the PrONTO Study, a clinical study of 40 patients with neovascular age-related macular degeneration AMD who received ocular injections of ranibizumab (LucentisTM). The PrONTO Study (Prospective Optical Coherence Tomography Imaging of Patients with Neovascular...
- Research articles 2006-05-08
- XOMA to Receive New Royalty Stream From Bacterial Production License; LUCENTIS™ is First Approved Drug Licensed Under XOMA's BCE Program
- BERKELEY, Calif. -- XOMA Ltd. (Nasdaq:XOMA) today announced that LUCENTISTM, owned by Genentech, Inc. (NYSE:DNA) and recently approved by the FDA for the treatment of neovascular wet age-related macular degeneration, is the first marketed therapeutic product by a licensee of XOMA's Bacterial Cell Expression BCE technology. XOMA will receive a...
- Research articles 2006-07-12
- Pilot Study to Assess Safety and Efficacy of Medidur™ FA in AMD Patients Treated With Lucentis®
- ATLANTA, May 8 /PRNewswire/ -- Alimera Sciences Inc., a privately held ophthalmic pharmaceutical company announced today that enrollment has begun for a pilot study to assess the safety and efficacy of Medidur FA in conjunction with LucentisR (ranibizumab injection, Genentech) in patients with exudative age-related macular degeneration wet AMD.
- Research articles 2008-05-08
- Little Difference Between Roche's Avastin and Lucentis for Macular Degeneration
- The Burrill Report submits: By Kristi Eaton A new study shows that a cancer drug is no different in effectiveness as a gold standard for macula degeneration. Researchers from Boston University School of Medicine and the VA Boston Healthcare System discovered there was no difference in efficacy between Genentech's...
- External links 2009-10-18
- Genentech - Avastin: United States Senate Special Committee on Aging
- KOHL PRAISES CMS DECISION TO REVERSE CODING REGULATION FOR EYE DRUG October 28, 2009 WASHINGTON – Today U.S. Senate Special Committee on Aging Chairman Herb Kohl (D-WI) praised the Centers for Medicare and Medicaid CMS...
- News items 2009-10-28
- FDA Slaps Down Genentech On Eye Drug
- The saga of Avastin and Lucentis -- two Genentech drugs used to treat a blinding condition called age-related macular degeneration, even though one is about 50 times cheaper than the other -- is one of those stories that just gets better the longer it goes on. A...
- Blog posts 2008-06-17
- DotW: Noble Pursuits
- It's Nobel week and the rewards and riches went to experts who've spent their careers ferreting out the secrets of telomeres medicine, ribosomes chemistry, and fiber optics physics. And then there was Barack Obama, who took home the much vaunted--and in this case highly controversial Nobel for Peace. Who needs...
- News items 2009-10-09
- British experts green light Novartis' sight-saving drug
- GENEVA AFP — Novartis said Wednesday its Lucentis eye treatment has been recommended by Britain's National Institute for Health and Clinical Excellence NICE as a cost-effective therapy to stave off blindness. The Swiss pharmaceutical giant said in a statement that NICE had recommended Lucentis as "a cost-effective therapy for...
- Research articles 2008-08-27
- Othera Pharmaceuticals Presents New AMD Data at Angiogenesis 2007 Symposium
- Preclinical data demonstrates the potential for a synergistic anti-angiogenic effect of OT-551 topical eye drop with Lucentis or Avastin injections to treat the wet form of AMD
- Research articles 2007-02-26
- Regeneron and Bayer HealthCare Initiate Phase 3 Global Development Program For VEGF Trap-Eye In Wet Age-Related Macular Degeneration
- Study will compare the VEGF Trap-Eye to ranibizumab (Lucentis([R]))
- Research articles 2007-08-03
- XOMA Limited Q4 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Our first question is from Michael King with Rodman & Renshaw. Please proceed with your question. Michael King - Rodman & Renshaw Thanks. Good afternoon, guys. Can you hear me? Steve Engle Yes. Thanks, Michael. Michael King - Rodman & Renshaw Let's see, maybe working...
- Earnings calls 2008-03-11
- PDL BioPharma Q4 2006 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. Our first question comes from the line of Joel Sendek with Lazard. Joel Sendek - Lazard Hi. Sorry, I'm at an airport. Two questions. The first, can you go over more of the guidance on cost of goods sold? It looks like...
- Earnings calls 2007-02-21
- Xoma Ltd. Q3 2008 Earnings Call Transcript
- Earnings Call ExcerptXoma Ltd. XOMA Q3 2008 Earnings Call November 10, 2008 4:30 pm ET Executives Steven Engle - Chairman and Chief Executive Officer Alan Solinger - Vice President of Clinical Immunology Analysts Aaron Lindberg - William Smith & Company Jason Kantor - RBC Capital Markets Jason Kolbert -...
- Earnings calls 2008-11-10
- FDA to Allow "Off-Label" Unapproved Drug Promotion
- The FDA has "finalized" guidelines allowing drug companies to promote drugs for unapproved ("off-label") uses. The guidelines will allow companies to distribute peer-reviewed scientific literature discussing off-label uses. Drug companies and their right-wing stalking horse, the Washington Legal Foundation, have been pushing for this move for years....
- Blog posts 2009-01-13
- Allergan Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions. Our first question comes from Gregg Gilbert of Bank of America-Merrill Lynch. Gregg Gilbert - Merrill Lynch Thanks, good morning. I'll ask my two product areas upfront. First for Scott on POSURDEX, do you haven't action date yet and can you offer us...
- Earnings calls 2009-02-04
- XOMA Ltd. Q2 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Certainly. Operator instructions. We will go first to Liana Moussatos with Wedbush. Liana Moussatos – Wedbush Thank you. Can you talk a little bit about the design of the phase II trial and when do you think you will release data? And then second, can you describe...
- Earnings calls 2009-08-07
- DotW: Same As The Old Boss
- Whiners, do-gooders and underdogs, go back to bed. Make yourselves some herbal tea. Go write in your journal or do a little scrapbooking. Maybe you'll feel better.This was not your week, in which we saw nothing less than the restoration of the natural order of the universe. Here's to the...
- News items 2009-10-23
- << Previous
- page 1 of 1
- Next >>
Presented by the Premiere Rewards Gold Card from American Express